Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
159
  1. Home
  3. Development Of A Predictive Model For Gastrointestinal Side Effects Of Metformin Treatment In Chinese Individuals With Type 2 Diabetes Based On Four Randomised Clinical Trials.
  1. Home
  3. Development Of A Predictive Model For Gastrointestinal Side Effects Of Metformin Treatment In Chinese Individuals With Type 2 Diabetes Based On Four Randomised Clinical Trials.

Related Experiment Video

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals

Weihao Wang1, Yujia Han2, Xun Jiang1,3

  • 1Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Diabetes, Obesity & Metabolism
|November 29, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
gastrointestinal side effectsmetforminprediction modeltype 2 diabetes

More Related Videos

Fixation and Operational Method for Abdominal Massage in T2DM Mice
06:00

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

150
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

973

Related Experiment Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K
Fixation and Operational Method for Abdominal Massage in T2DM Mice
06:00

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

150
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

973

This study developed a predictive model to identify patients likely to experience gastrointestinal side effects from metformin. The model uses easily obtainable features, aiding clinical practice for type 2 diabetes management.

Area of Science:

  • Pharmacovigilance and predictive modeling in diabetes care.
  • Application of machine learning in clinical risk assessment.

Background:

  • Metformin is a first-line treatment for type 2 diabetes.
  • Gastrointestinal side effects are common with initial metformin use, impacting patient adherence.
  • Predictive tools are needed to identify at-risk individuals.

Purpose of the Study:

  • To develop a model-based predictive approach for gastrointestinal side effects of initial metformin medication.
  • To identify key clinical indicators for predicting these side effects.
  • To create an accessible tool for clinical application.

Main Methods:

  • Utilized data from four randomized clinical cohorts (1736 patients with type 2 diabetes).
  • Employed ten machine learning models, with Extra Tree showing the highest performance (AUC=0.87).
  • Identified key predictors including blood urea nitrogen, sex, triglycerides, HDL-C, and total cholesterol.

    • Main Results:

    • A simplified predictive model using five key indicators achieved an AUC of 0.76.
    • An online web-based tool was developed integrating 17 features and the top five indicators.
    • The Extra Tree model demonstrated strong predictive accuracy in validation and test sets.

    Conclusions:

    • A predictive model using easily obtainable features can effectively identify patients at risk of gastrointestinal side effects from metformin.
    • The developed model is suitable for clinical application, particularly in the Chinese population.
    • This tool can aid in personalized metformin initiation and management.